RESUMEN
BACKGROUND: This article presents results of the acute treatment phase of a 2-site study comparing cognitive behavioral group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia. METHODS: One hundred thirty-three patients from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educational-supportive group therapy (an attention-placebo treatment of equal credibility to CBGT). The "allegiance effect," ie, the tendency for treatments to seem most efficacious in settings of similar theoretical orientation and less efficacious in theoretically divergent settings, was also examined by comparing responses to the treatment conditions at both sites: 1 known for pharmacological treatment of anxiety disorders and the other for cognitive behavioral treatment. RESULTS: After 12 weeks, phenelzine therapy and CBGT led to superior response rates and greater change on dimensional measures than did either control condition. However, response to phenelzine therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 weeks on some measures. There were few differences between sites, suggesting that these treatments can be efficacious at facilities with differing theoretical allegiances. CONCLUSIONS: After 12 weeks, both phenelzine therapy and CBGT were associated with marked positive response. Although phenelzine therapy was superior to CBGT on some measures, both were more efficacious than the control conditions. More extended cognitive behavioral treatment and the combination of modalities may enhance treatment effect.
Asunto(s)
Terapia Cognitivo-Conductual , Fenelzina/uso terapéutico , Trastornos Fóbicos/terapia , Psicoterapia de Grupo , Adulto , Análisis de Varianza , Animales , Terapia Combinada , Femenino , Estudios de Seguimiento , Cobayas , Humanos , Masculino , Persona de Mediana Edad , Inventario de Personalidad , Trastornos Fóbicos/tratamiento farmacológico , Trastornos Fóbicos/psicología , Placebos , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Resultado del TratamientoRESUMEN
BACKGROUND: Uncontrolled reports suggest that intravenous clomipramine hydrochloride may be effective for patients with obsessive-compulsive disorder (OCD) who are nonresponsive to oral clomipramine. METHODS: Fifty-four patients with oral clomipramine-refractory OCD were randomized to receive 14 infusions of either placebo or clomipramine hydrochloride, starting at 25 mg/d and increasing to 250 mg/d. Ratings were conducted double-blind after infusion 14 among 54 patients, single-blind 1 week later among 39 patients, and nonblind 1 month later among 31 patients. Response was based on a Clinical Global Impressions rating of at least "much improved." RESULTS: Six (21%) of 29 patients randomized to receive intravenous (i.v.) clomipramine vs 0 of 25 patients given i.v. placebo were responders after 14 infusions (df = 1, P<.02). Dimensional ratings after infusion 14 revealed significant (P = .007) improvement on the National Institute of Mental Health-Obsessive-Compulsive Scale and the Clinical Global Impressions Scale (P = .03), but not the Yale-Brown Obsessive Compulsive Scale. One week later, all dimensional measures of OCD showed significant improvement. At 1 week post-i.v., 9 (43%) of 21 patients initially randomized to i.v. clomipramine and treated subsequently with oral clomipramine were responders, whereas 0 of 18 patients initially randomized to receive i.v. placebo and treated subsequently with several days of open-label i.v. clomipramine responded (df = 1, P<.002). Of the 31 patients assessed 1 month after i.v. infusion (treatment not controlled), 18 (58.1%) were responders. Intravenous clomipramine treatment was safe with no serious adverse consequences. CONCLUSIONS: Intravenous clomipramine is more effective than i.v. placebo for patients with OCD with a history of inadequate response or intolerance to oral clomipramine. Further study of this promising treatment for refractory OCD is needed.
Asunto(s)
Clomipramina/uso terapéutico , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Administración Oral , Adulto , Clomipramina/administración & dosificación , Método Doble Ciego , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Infusiones Intravenosas , Masculino , Trastorno Obsesivo Compulsivo/psicología , Placebos , Escalas de Valoración Psiquiátrica , Resultado del TratamientoAsunto(s)
Inhibidores de la Monoaminooxidasa/uso terapéutico , Trastornos Fóbicos/tratamiento farmacológico , Selegilina/uso terapéutico , Adulto , Análisis de Varianza , Femenino , Humanos , Masculino , Escalas de Valoración Psiquiátrica/normas , Inducción de Remisión/métodos , Selegilina/efectos adversos , Ajuste SocialRESUMEN
BACKGROUND: Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia. METHOD: Seventy-seven non-responders to one week of single-blind placebo were randomly assigned to moclobemide or placebo for eight weeks of double-blind treatment. Outcome was assessed by independent evaluator, treating psychiatrist and self-ratings. After eight weeks, patients who were at least minimally improved continued treatment for a further eight weeks. RESULTS: Intention-to-treat sample response rates at week 8 were 7/40 (17.5%) for the moclobemide group and 5/37 (13.5%) for placebo (NS). Moclobemide was significantly superior to placebo on 2 of 10 primary outcome measures. Moclobemide was well tolerated. CONCLUSIONS: Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small.
Asunto(s)
Benzamidas/uso terapéutico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Trastornos Fóbicos/tratamiento farmacológico , Adolescente , Adulto , Anciano , Benzamidas/efectos adversos , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Moclobemida , Inhibidores de la Monoaminooxidasa/efectos adversos , Estudios Prospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
We report the results of an 8-week open trial of imipramine in 15 patients with social phobia. Nine patients completed the trial; six dropped out early because of adverse effects. The mean reduction in the Liebowitz Social Anxiety Scale was 15% and 18% for the intent-to-treat and completer groups, respectively; the overall response rate (based on the Clinical Global Impression Scale of 1 or 2, very much or much improved) was 20% (3/15) and 22% (2/9), respectively. The results from this open trial do not support the efficacy of imipramine as a treatment for social phobia.
Asunto(s)
Antidepresivos Tricíclicos/uso terapéutico , Imipramina/uso terapéutico , Trastornos Fóbicos/tratamiento farmacológico , Adulto , Antidepresivos Tricíclicos/efectos adversos , Femenino , Humanos , Imipramina/efectos adversos , Masculino , Persona de Mediana Edad , Trastornos Fóbicos/psicología , Escalas de Valoración Psiquiátrica , Método Simple CiegoRESUMEN
The symptom overlap between posttraumatic stress disorder (PTSD) and other pharmacotherapy-responsive disorders suggests that pharmacotherapy might be effective. Nevertheless, of the eight published placebo-controlled trials investigating the pharmacotherapy of PTSD, only four found statistically significant efficacy for the treatment being studied. This literature possesses a number of methodologic limitations, including the fact that most studies have been conducted with war veterans, who may constitute a more treatment-refractory population. Several open trials and one controlled trial with selective serotonin reuptake inhibitors have reported improvement in some or all core PTSD symptoms (reexperiencing, avoidance, numbing, and hyperarousal). The authors hypothesized that paroxetine might be effective in PTSD, based on findings of its particular efficacy for anxiety and agitation in studies of depressed patients. The study presented here summarizes a 12-week, open-label trial of paroxetine among patients with noncombat-related, chronic PTSD. Outcome was assessed by an independent evaluator, the treating physician, and the patient, with the use of established rating scales for depression, anxiety, general symptoms, and PTSD core symptoms. A repeated-measures analysis of variance revealed highly significant improvement in all three symptom clusters, as well as in associated anxiety, depressive, and dissociative symptoms, with 11 of 17 (65%) patients rated as much or very much improved. The mean reduction in PTSD symptom scores was 48%. Exploratory analyses revealed that cumulative childhood trauma was negatively correlated with pharmacotherapy response (r = -0.52, p = 0.03). There was also significant variation in the time course of response across symptom clusters, which is suggestive of multiple mechanisms of response. Because paroxetine seems a highly promising treatment for all three symptom clusters of PTSD, a placebo-controlled clinical trial is warranted.
Asunto(s)
Antidepresivos de Segunda Generación/uso terapéutico , Paroxetina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Trastornos por Estrés Postraumático/tratamiento farmacológico , Adulto , Femenino , Humanos , Masculino , Trastornos por Estrés Postraumático/patologíaRESUMEN
BACKGROUND: Controlled trials suggest that clomipramine may be a highly effective antipanic drug. Lowering the starting dose may alleviate troublesome initial side effects and increase acceptability and compliance. METHOD: Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment. Starting at 10 mg/day, the dose was gradually increased to a mean dose of 97 mg/day. RESULTS: While completers showed highly significant improvement, the benefits were severely limited by a high dropout rate due to adverse reactions occurring mostly during the first 2 weeks of treatment. CONCLUSION: Given the alternatives, clomipramine should not be used as a first-line antipanic medication.
Asunto(s)
Antidepresivos Tricíclicos/uso terapéutico , Clomipramina/uso terapéutico , Trastorno de Pánico/tratamiento farmacológico , Adulto , Anciano , Agorafobia/tratamiento farmacológico , Agorafobia/epidemiología , Antidepresivos Tricíclicos/efectos adversos , Clomipramina/administración & dosificación , Clomipramina/efectos adversos , Comorbilidad , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastorno de Pánico/epidemiología , Trastorno de Pánico/psicología , Pacientes Desistentes del Tratamiento , Escalas de Valoración Psiquiátrica , Índice de Severidad de la Enfermedad , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Resultado del TratamientoAsunto(s)
Ondansetrón/uso terapéutico , Trastorno de Pánico/tratamiento farmacológico , Administración Oral , Adulto , Agorafobia/diagnóstico , Agorafobia/tratamiento farmacológico , Agorafobia/psicología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ondansetrón/efectos adversos , Trastorno de Pánico/diagnóstico , Trastorno de Pánico/psicología , Inventario de Personalidad , Trastornos Fóbicos/diagnóstico , Trastornos Fóbicos/tratamiento farmacológico , Trastornos Fóbicos/psicología , Proyectos Piloto , Resultado del TratamientoRESUMEN
This article addresses the diagnosis and pharmacologic treatment of hypochondriasis. Diagnostic issues are reviewed briefly, focusing on the need for a thorough medical re-consideration of the patient's presenting symptoms. Because the diagnosis rests on the absence of a medical cause to account for the presence or intensity of the physical symptoms, neither self-report forms nor non-medically trained interviewers should be used to definitively make the diagnosis of hypochondriasis. We review the case reports and small uncontrolled series on the pharmacologic treatment of hypochondriasis, emphasizing the growing body of evidence suggesting particular efficacy for the serotonin reuptake inhibitors. Preliminary results from an ongoing placebo-controlled trial of hypochondriasis using fluoxetine are presented. While the controlled trial supports the open treatment data in revealing a high rate of improvement among patients completing treatment with fluoxetine, it also demonstrates that many patients respond to placebo as well. In conclusion, although the traditional nihilistic attitude regarding the possibility of successful treatment of hypochondriacs appears no longer warranted, the question remains open as to whether SSRIs have particular efficacy in patients with hypochondriasis or whether nonspecific treatment effects are the primary cause of improvement.
Asunto(s)
Hipocondriasis/tratamiento farmacológico , HumanosRESUMEN
The psychological and physiological effects of acute low-potency benzodiazepine administration on lactate-induced panic were examined in 10 patients with panic disorder (PD). The patients, who had panicked during a standard sodium-lactate infusion, underwent a repeat infusion modified by pretreatment with intravenous diazepam (5 mg). Acute Panic Inventory (API) scores preceding the second lactate infusion, which were associated with diazepam pretreatment, were significantly reduced in compared with those measured before the first lactate infusion. However, the second visit "fear of doom" item of the API was significantly reduced relative to the same time point of the first visit 35 min before lactate infusion, when diazepam had not yet been administered. Thus, the reduction of prelactate anxiety preceding the second infusion appeared to reflect both pharmacological and nonpharmacological contributions. The diazepam pretreatment condition was associated with a significantly increased infusion duration and a significant attenuation of rate of API symptom increase in response to lactate. Despite significant attenuation of lactate infusion effects associated with the diazepam pretreatment condition, 7 of 10 patients experienced a second panic attack. This pilot study suggests that diazepam pretreatment is associated with a marked reduction of symptomatic response during a second lactate infusion, although the magnitude of attenuation observed was insufficient to block lactate-induced panic in a majority of lactate-vulnerable PD patients.
Asunto(s)
Agorafobia/diagnóstico , Ansiolíticos/administración & dosificación , Diazepam/administración & dosificación , Lactatos , Trastorno de Pánico/diagnóstico , Pánico/efectos de los fármacos , Adulto , Agorafobia/fisiopatología , Nivel de Alerta/efectos de los fármacos , Nivel de Alerta/fisiología , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Miedo/efectos de los fármacos , Miedo/fisiología , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Humanos , Infusiones Intravenosas , Ácido Láctico , Masculino , Persona de Mediana Edad , Pánico/fisiología , Trastorno de Pánico/fisiopatología , Premedicación , Método Simple CiegoRESUMEN
BACKGROUND: This study examined the nature of impairment of functioning in persons with social phobia and assessed the validity of two new rating scales for describing impairment in social phobia. METHOD: In 32 patients with social phobia and 14 normal control subjects, impairment was assessed using the Disability Profile and the Liebowitz Self-Rated Disability Scale, new instruments designed to provide clinician- and patient-rated descriptive measures of current and lifetime functional impairment related to emotional problems. Validity of the new scales was assessed by measuring internal consistency, comparing scores for patients and controls, and comparing scores with those on standard measures of disability, social phobia symptoms, and social support. RESULTS: More than half of all social phobic patients reported at least moderate impairment at some time in their lives, due to social anxiety and avoidance, in areas of education, employment, family relationships, marriage/romantic relationships, friendships/social network, and other interests. Social phobic patients were rated more impaired than normal controls on nearly all items on both measures. Both scales were internally consistent, with Cronbach's alpha coefficients for lifetime and current disability subscales in the range of .87 to .92. Significant positive correlations of scores on the new scales with scores on coadministered standard scales of social phobia symptoms and disability demonstrated concurrent validity. Disability was not significantly correlated with measures of social support. CONCLUSION: Social phobia is associated with impairment in most areas of functioning, and the new scales appear useful in assessing functional impairment related to social phobia.
Asunto(s)
Trastornos Fóbicos/diagnóstico , Escalas de Valoración Psiquiátrica , Actividades Cotidianas , Adulto , Evaluación de la Discapacidad , Familia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inventario de Personalidad , Trastornos Fóbicos/clasificación , Trastornos Fóbicos/psicología , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Psicometría , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Ajuste SocialRESUMEN
The novel anxiolytic agent buspirone has been shown to be effective in generalized anxiety disorder, but its utility in phobic disorders is less clear. We examined its efficacy in social phobia in a 12-week open trial. Twenty-one patients who met DSM-III-R criteria for social phobia and who did not respond to 1 week of single-blind placebo were treated with buspirone, and 17 completed a minimum of 2 weeks of treatment. Twelve of these 17 patients met criteria for the generalized subtype of social phobia. At week 12, 8 (47%) of the 17 patients were rated much to very much improved in social phobia symptoms on the Clinical Global Impression Scale. Of the 12 patients who were able to tolerate a dose of 45 mg/day or more, 9 (67%) were at least much improved. Significant improvement was noted on measures of social anxiety and avoidance of social situations. Ratings of generalized anxiety and depression, which were low at baseline, did not change significantly during treatment. The results suggest that buspirone may have modest efficacy in the treatment of social phobia, but confirmation in a placebo-controlled trial is required.
Asunto(s)
Buspirona/uso terapéutico , Trastornos Fóbicos/tratamiento farmacológico , Adulto , Buspirona/administración & dosificación , Buspirona/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Fóbicos/psicología , Escalas de Valoración Psiquiátrica , Método Simple CiegoRESUMEN
Alpidem, an imidazopyridine that acts at the gamma-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8-week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.
Asunto(s)
Agorafobia/tratamiento farmacológico , Ansiolíticos/uso terapéutico , Imidazoles/uso terapéutico , Trastorno de Pánico/tratamiento farmacológico , Piridinas/uso terapéutico , Adolescente , Adulto , Anciano , Agorafobia/psicología , Ansiolíticos/efectos adversos , Terapia Combinada , Desensibilización Psicológica , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Imidazoles/efectos adversos , Masculino , Persona de Mediana Edad , Trastorno de Pánico/psicología , Inventario de Personalidad , Piridinas/efectos adversos , Método Simple CiegoRESUMEN
Seventy-four patients who met DSM-III criteria for social phobia completed 8 weeks of double-blind, randomly assigned treatment with the monoamine oxidase inhibitor phenelzine sulfate, the cardioselective beta-adrenergic blocker atenolol, or placebo. The overall response rates were 64% for phenelzine, 30% for atenolol, and 23% for placebo. Phenelzine was widely superior to both atenolol and placebo on independent rater analyses and, to a lesser extent, on self-report, with no significant differences between atenolol and placebo. At the end of 16 weeks, phenelzine was still significantly superior to placebo, while atenolol showed an intermediate response that did not differ significantly from either of the other treatments. Patients with generalized social phobia constituted 76% of the sample, and they were preferentially responsive to phenelzine. The small size of the discrete social phobic sample precluded separate outcome analyses for this subtype. Overall, the findings support the responsivity of social phobia to monoamine oxidase inhibitors.
Asunto(s)
Atenolol/uso terapéutico , Fenelzina/uso terapéutico , Trastornos Fóbicos/tratamiento farmacológico , Adolescente , Adulto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inventario de Personalidad , Trastornos Fóbicos/diagnóstico , Trastornos Fóbicos/psicología , Placebos , Prevalencia , Escalas de Valoración Psiquiátrica , Índice de Severidad de la EnfermedadRESUMEN
To assess the role of noradrenergic stimulation during lactate-induced panic, ten patients with panic disorder who panicked during a standard sodium-lactate infusion underwent a repeat infusion following intravenous clonidine pretreatment. Although clonidine significantly lowered prelactate systolic blood pressure, the drug did not significantly lower prelactate anxiety levels, as reflected by the Acute Panic Inventory (API). Clonidine blocked lactate-induced panic in four of ten subjects, a significant effect. Clonidine treatment also significantly attenuated lactate-panic symptoms, as reflected by time to panic and API comparison between trials. Nevertheless, over half the subjects still panicked in response to lactate despite clonidine. This preliminary study suggests that reduction of central noradrenergic activity by clonidine, at least at the dosage levels employed in the current study, only partially attenuates panic response to lactate. Noradrenergic theories of panic may not therefore fully account for lactate panicogenesis.
Asunto(s)
Clonidina/farmacología , Lactatos , Trastorno de Pánico/inducido químicamente , Adulto , Presión Sanguínea/efectos de los fármacos , Clonidina/administración & dosificación , Clonidina/uso terapéutico , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Infusiones Intravenosas , Ácido Láctico , Masculino , Persona de Mediana Edad , Trastorno de Pánico/diagnóstico , Trastorno de Pánico/prevención & control , Trastorno de Pánico/psicología , Inventario de PersonalidadRESUMEN
In a preliminary trial, five oral-clomipramine-refractory patients with obsessive-compulsive disorder (OCD) were treated openly with 14 intravenous clomipramine infusions each. Using standardized assessments, three patients were rated as much improved, one as unchanged, and one as minimally improved. Statistically significant improvements were noted on both the Yale-Brown Obsessive Compulsive Scale and the NIMH Global OCD scores. No patient discontinued treatment because of side effects. Although the results are provocative in that three of five patients were much improved at the end of the protocol, conclusions about preferential efficacy for the intravenous route must await a placebo-controlled trial.
Asunto(s)
Clomipramina/administración & dosificación , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Administración Oral , Adulto , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Trastorno Obsesivo Compulsivo/psicología , Inventario de PersonalidadRESUMEN
Social phobia is emerging as an important cause of psychiatric morbidity. Reasons for this are described, as are clinical issues of importance to social phobia, including the extensive associated distress and disability. The use of phenelzine, atenolol, buspirone, fluoxetine, and moclobemide are described. Diagnostic and transcultural aspects of social phobia are described.
Asunto(s)
Trastornos Fóbicos/tratamiento farmacológico , Adolescente , Atenolol/uso terapéutico , Benzamidas/uso terapéutico , Buspirona/uso terapéutico , Niño , Ensayos Clínicos como Asunto , Femenino , Fluoxetina/uso terapéutico , Humanos , Masculino , Moclobemida , Fenelzina/uso terapéutico , Trastornos Fóbicos/diagnóstico , Trastornos Fóbicos/psicología , PlacebosRESUMEN
Moral or religious scrupulosity is a disabling condition which is sometimes seen in patients with obsessive compulsive disorder (OCD). The authors described 10 patients with moral or religious scrupulosity who were treated with fluoxetine or clomipramine. Seven of the 10 patients completed open treatment of at least 8 weeks without requiring adjunctive medication; 5 of those 7 patients were rated as much improved. Among the 3 patients who required adjunctive medication, 1 was rated as much improved. Of the 4 nonresponders at 3 months, 2 responded after longer treatment trials. These results suggest that extreme moral or religious concerns and behaviors might be a form of OCD and that the scrupulosity can be effectively treated with serotonin reuptake blockers.
Asunto(s)
Clomipramina/uso terapéutico , Fluoxetina/uso terapéutico , Principios Morales , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Religión y Psicología , Adolescente , Adulto , Anciano , Catolicismo , Quimioterapia Combinada , Femenino , Humanos , Judaísmo , Masculino , Persona de Mediana Edad , Trastorno Obsesivo Compulsivo/psicología , Evaluación de Procesos y Resultados en Atención de Salud , Escalas de Valoración PsiquiátricaRESUMEN
Some forms of anxiety and affective disorder, such as panic disorder and major depression, appear distinct, while other forms, such as generalized anxiety disorder and chronic depression or dysthymia, may lie on a continuum and blend with each other. However, even panic disorder and major depression have many common features. Moreover, for reasons not yet clear, they occur together frequently, and their combined occurrence in the same patient has been associated with greater severity and chronicity, decreased treatment responsiveness, and, possibly, increased familial prevalence of anxiety and/or depression. Finally, studies of primary care patients suggest the frequent occurrence of a mixed anxiety-depressive disorder that may often be subsyndromal by DSM-III-R criteria but is nevertheless associated with prominent distress and/or impairment.
Asunto(s)
Trastornos de Ansiedad/diagnóstico , Trastorno Depresivo/diagnóstico , Trastornos de Ansiedad/psicología , Trastorno Depresivo/psicología , Humanos , Pánico , Escalas de Valoración Psiquiátrica , SíndromeRESUMEN
Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.